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Abstract
Background: All‐cause mortality has been suggested as an end‐point in cancer 
screening trials in order to avoid biases in attributing the cause of death. The aim 
of this study was to investigate which sample size and follow‐up is needed to find a 
significant reduction in all‐cause mortality.
Methods: A literature review was conducted to identify previous studies that mod-
eled the effect of screening on all‐cause mortality. Microsimulation modeling was 
used to simulate breast cancer, lung cancer, and colorectal cancer screening trials. 
Model outputs were: cancer‐specific deaths, all‐cause deaths, and life‐years gained 
per year of follow‐up.
Results: There were large differences between the evaluated cancers. For lung cancer, 
when 40 000 high‐risk people are randomized to each arm, a significant reduction in 
all‐cause mortality could be expected between 11 and 13 years of follow‐up. For breast 
cancer, a significant reduction could be found between 16 and 26 years of follow‐up for 
a sample size of over 300 000 women in each arm. For colorectal cancer, 600 000 per-
sons in each arm were required to be followed for 15‐20 years. Our systematic literature 
review identified seven papers, which showed highly similar results to our estimates.
Conclusion: Cancer screening trials are able to demonstrate a significant reduction in 
all‐cause mortality due to screening, but require very large sample sizes. Depending 
on the cancer, 40 000‐600 000 participants per arm are needed to demonstrate a sig-
nificant reduction. The reduction in all‐cause mortality can only be detected between 
specific years of follow‐up, more limited than the timeframe to detect a reduction in 
cancer‐specific mortality.
K E Y W O R D S
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1 |  INTRODUCTION
Cancer screening trials generally use cancer‐specific mor-
tality as an endpoint.1,2 This has been criticized because of 
possible biases in determination of the cause of death.1,3,4 
The first is slippery linkage bias: screening or the resulting 
diagnosis or treatment may lead to deaths that cannot be eas-
ily linked to the screening. Therefore, these individuals will 
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be classified under other cause deaths, instead of deaths re-
lated to the cancer. Because more people in the screen arm 
can experience this cause of death, this bias is in favor of 
screening.1 The second is sticky diagnosis bias: because 
the target cancer will be diagnosed more frequently in the 
screened group than in the control group, deaths may be more 
likely to be attributed to the target cancer in the screened 
group. Therefore, the cancer‐specific mortality will be biased 
against screening.1 Third, a decrease in cancer specific mor-
tality should not be counter parted by an increase in deaths 
from other causes (corrected for follow‐up).
All‐cause mortality is not affected by these biases. 
However, the major drawback is that since only a few percent 
of individuals in a screening trial will die from the cancer 
for which is being screened, the power of a screening trial to 
detect a difference in all‐cause mortality is very low. Even the 
most common cancers account for only 3%‐4% of all deaths. 
Thus, a 20% cancer‐specific mortality reduction would 
translate to at most a 0.8% reduction in all‐cause mortality. 
Therefore, to detect a significant reduction in all‐cause mor-
tality the trial would require a large sample size, estimated to 
up to 2.6 million participants.5-9 Nevertheless, there are many 
reviews and commentaries published to criticize screening 
trials for the lack of a reduction in all‐cause mortality, for 
example.3,10-12
To date, the only cancer screening trial targeting a sin-
gle cancer type, which showed a significantly reduced all‐
cause mortality is the US National Lung Cancer Screening 
Trial.13 In this trial 26 722 participants were randomized to 
low‐dose computed tomography (CT) screening and 26 732 
participants to chest radiography screening. After 6.5 years of 
follow‐up the lung cancer mortality rate ratio (RR) was 0.80 
(95% confidence interval (CI): 0.73‐0.93) for the CT arm, 
compared to the radiography arm, and the all‐cause mortality 
rate ratio was 0.93 (95%CI: 0.86‐0.99).13
No other cancer screening trials have shown a significant 
difference in all‐cause mortality. Even some large trials (more 
than 100  000 participants) such as the Two‐county (breast 
cancer),14,15 ERSPC (prostate cancer),16 PLCO, UKFSST, and 
Nottingham (colorectal cancer),17-19 that did show a reduction 
in cancer‐specific mortality failed to show a statistically sig-
nificant effect in all‐cause mortality. A meta‐analysis of the 
Swedish breast cancer trials (247 010 participants) showed a 
nonsignificant effect on all‐cause mortality (RR 0.98; 95%CI: 
0.96‐1.00).14 For colorectal cancer, a meta‐analysis of four 
flexible sigmoidoscopy trials, including 458 000 participants, 
found a statistically significant effect on all‐cause mortality 
(RR 0.975; 95%CI: 0.959‐0.992).20 Recently, the Prostate 
Lung Colorectal Ovarian (PLCO) trial including 154 887 par-
ticipants screened for three cancers showed a reduction in all‐
cause mortality (RR 0.966; 95%CI: 0.943‐0.989).21
Aside from the cause of death, the timing of evaluating 
the effects of screening is also important.22 In the first years 
after the start of a screening trial, no substantial difference 
in cancer‐specific or all‐cause mortality can be expected. 
However, after a long follow‐up, when almost all participants 
have died, no difference in all‐cause mortality can be ex-
pected, while a reduction in cancer‐specific mortality could 
still be detected.
The aim of this study was to assess in three simulated 
screening trials (lung, breast, and colorectal cancer): (a) the 
current available evidence on the possible effect of screening 
on all‐cause mortality; and (b) the sample size and follow‐up 
period to find an all‐cause mortality reduction due to cancer 
screening. The results of this study can be used to inform 
the debate on all‐cause mortality as an endpoint of screening 
trials.
2 |  METHODS
2.1 | Systematic review
We performed a systematic review to find previous mod-
eling studies that have evaluated the effect of screening 
programs on all‐cause mortality through Scopus and Web 
of Science databases. The query consisted of four linked 
baskets of keywords. The first basket was the cancer sites: 
breast, lung, colorectal (colon and rectal were also used 
separately). The second focused on synonyms for screen-
ing (including early diagnosis, early detection, and cancer 
prevention). The third basket focused on combinations of 
phrases describing outcomes, including all‐cause mortal-
ity, overall mortality, all‐cause death, and overall death. 
The fourth basket included keywords for modeling. In case 
of Scopus, keywords were limited to title/abstract for the 
phrases describing the cancer types and screening. In both 
databases two additional filters were applied: Article or 
Review type records + English language records (Appendix 
1). The records from the databases were downloaded on 20 
November 2018.
The hits were checked for duplicates. All papers were 
screened for title and abstract by two independent research-
ers. On the basis of the predefined study eligibility criteria, 
we defined the following exclusion categories: no abstract/no 
author, not lung/breast/colorectal cancer, not cancer screen-
ing, not modeling, no mortality data. Disagreements between 
the independent researchers regarding the inclusion were re-
solved by consensus. Two independent researchers conducted 
the full‐text review of all included papers. The full‐text re-
view applied the following exclusion criteria: no population 
level data on overall mortality or life‐years gained, data are 
not based on modeling and data are available only on life‐
years gained.
The included articles were subjected to duplicated 
data extraction completed by two experts independently. 
Disagreements were resolved by consensus.
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2.2 | MISCAN modeling
To evaluate the effect of screening on cancer‐specific mor-
tality, all‐cause mortality, and life‐years gained, we used 
the MIcrosimulation SCreening ANalysis (MISCAN) lung, 
breast, and colorectal cancer models. The natural history 
of cancer is modeled by a progression through preclinical 
stages. At each preclinical stage, a tumor may be clinically 
diagnosed or progress to the next preclinical stage. Screening 
may detect the tumor in an earlier preclinical stage, which 
can improve the prognosis.
The lung cancer model uses a two‐stage clonal expansion 
model which estimates a person's risk of lung cancer as a 
function of age and smoking history. The model simulates the 
natural history of lung cancer for four different histologies: 
adenocarcinoma, squamous cell carcinoma, other non‐small‐
cell carcinoma, and small cell carcinoma. The parameters of 
the model are calibrated to the NLST and the PLCO trial.13,23 
A detailed description of the model can be found in ten Haaf 
et al 2015.24
In the breast cancer model, the natural history of breast 
cancer is modeled as a progression through five preclinical 
stages (DCIS, T1A, T1B, T1C, and T2+). Survival after clini-
cal diagnosis or screen detection is based on data of the Dutch 
nationwide screening program. Survival rates after screen de-
tection are estimated using data from the Swedish randomized 
controlled trials.14,15,25,26 Probabilities of receiving adjuvant 
treatment (hormonal therapy, chemotherapy, or a combina-
tion of the two) and survival rates are incorporated using data 
from Dutch regional comprehensive cancer centers (by age, 
stage, and calendar year) and from the Early Breast Cancer 
Trialists' Collaborative Group (EBCTCG) meta‐analysis.27 A 
detailed description of the model has been published before.28
In the colorectal model, multiple adenomas can occur and 
can progress from small (<5 mm), to medium (6‐9 mm) to 
large adenomas (>10 mm) and eventually to cancer stage I‐
IV. The parameters of the model were calibrated using data 
on the age‐specific, stage‐specific, and localization‐specific 
incidence of colorectal cancer in the Netherlands (before the 
introduction of screening), the age‐specific prevalence of ad-
enomas as reported in autopsy studies, and the results of sev-
eral screening trials.17,29,30 The model is described in detail in 
van der Meulen et al.31
Three hypothetical cancer screening trials were modeled: 
annual CT lung cancer screening for ages 55‐80 for men and 
women who smoked at least 30 pack‐years and who cur-
rently smoke or quit less than 15  years ago (United States 
Preventive Services Task Force recommendations); biennial 
breast cancer mammography screening for women between 
ages 50‐69; and one‐time flexible sigmoidoscopy for men 
and women between age 55‐75. The attendance rates were 
assumed to be 75% for lung cancer, 80% for breast cancer, 
and 73% for colorectal cancer. In the simulated control arms 
participants were not screened. We modeled populations with 
a uniform age distribution among the eligible screening ages 
at the start of each trial, because most trials are designed that 
way. Therefore, some of the simulated individuals will have 
had only one invitation to attend a screen. The models used 
a cure rate to model the effect of screening: patients with a 
screen detected cancer were either cured (and did not die from 
the cancer anymore) or were not cured and died at the same 
time they would have died without having been screened. 
The proportion that was cured, and the baseline survival were 
both dependent on cancer stage and age at diagnosis. In the 
colorectal model, screen detected cases were assigned a one‐
stage better survival than the one for the clinically detected 
cases. This was because the stage‐specific survival of screen‐
detected colorectal cancer cases as seen in RCTs on guaiac 
fecal occult blood testing was substantially more favorable 
than that of clinically detected colorectal cancer, even after 
correcting for lead‐time bias.32
The output of the models were the number of cancer‐
specific deaths, all‐cause deaths, and the life‐years (until 
all‐cause death), for each year of follow‐up. The simula-
tions were performed with a sample size of 10 million peo-
ple eligible for screening, to reduce stochastic variation. 
For each year of follow‐up a 95% confidence interval (2‐
sided) was calculated for the relative incidence rate ratios 
for the number of cancer‐specific and all‐cause deaths in 
each arm. When the confidence interval of the rate ratio 
was below 1 the results was determined statistically signif-
icant. The outputs of the runs were used to estimate the ex-
pected effects when using sample sizes between 2000 and 
600 000 (in different step sizes as demonstrated in Figures 
2-4) individuals in each arm, scaled from the 10 million 
simulated.
3 |  RESULTS
3.1 | Systematic review
The search resulted in 799 hits in Scopus and 594 in Web 
of Science. After removing 143 duplicates, 1250 records 
were screened. The title/abstract screening resulted in 103 
papers eligible for full‐text screening. The full‐text screen-
ing yielded seven papers to include for data extraction. The 
complete flowchart of the literature review (based on the 
PRISMA statement33) is described in Figure 1.
Out of the seven modeling papers, three investigated lung 
cancer screening with CT,34-36 two mammography screen-
ing,37,38 one FOBT testing,39 and one mammography and 
sigmoidoscopy9 (Table 1). Four papers used a simple math-
ematical calculation to estimate the effect of screening, one 
used a Markov model, one applied patient level microsimu-
lation, and in one case the study design was not clear. Four 
papers were studying European populations, two the US and 
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one the Australian population. Although most papers included 
did not report whether the all‐cause mortality reduction was 
significant and the reductions were small: 1.4%‐3.6% for lung 
cancer, 0.4%‐1.8% for breast cancer, and 0.5%‐1.2% for col-
orectal cancer (Table 1).
3.2 | Modeling
3.2.1 | Lung cancer
In the control arm there were 96 lung cancer deaths per 1000 
high‐risk participants after life‐time follow‐up (Table 2), 
compared to 76 in the screen arm (17% less). The maximum 
difference in all‐cause mortality was 10 deaths after 15 years. 
In total, 1000 high‐risk participants in the screened arm lived 
195 years longer (on average 71 days per participant, or 9.8 
life‐years saved per lung cancer death prevented). A signifi-
cant difference in lung cancer mortality could be shown after 
16  years of follow‐up for a sample size of 2000 high‐risk 
people in each arm (Figure 2). With larger sample sizes, a 
significant difference could be found after 3 years. To show 
a significant effect in all‐cause mortality, 11‐13 years of fol-
low‐up, and minimal 40 000 high‐risk persons were needed 
in each arm.
3.2.2 | Breast cancer
There were 29 breast cancer deaths per 1000 women in 
the control arm after life‐time follow‐up (Table 2) and 22 
in the screen arm (24% less). The maximum difference in 
all‐cause mortality was four deaths after 25 years. In total, 
1000 women in the screened arm lived 88 years longer (on 
average 32 days per woman, or 12.6 life‐years saved per 
breast cancer death prevented). In the simulated cancer 
trial, 6000 women in each arm were needed to show a sig-
nificant difference on breast cancer mortality after 21 years 
of follow‐up (Figure 3). With increasing sample size, a sig-
nificant difference could be shown after 3  years. A sig-
nificant difference in all‐cause mortality could be expected 
between 16‐26  years of follow‐up and a minimal sample 
size of more than 300 000 women in each arm.
3.2.3 | Colorectal cancer
In the control arm there were 23 colorectal cancer deaths 
per 1000 participants after life‐time follow‐up (Table 2), 
compared to 18 in the screen arm (22% less). The maxi-
mum difference in all‐cause mortality was two deaths after 
10‐20 years. In total, 1000 participants in the screened arm 
F I G U R E  1  PRISMA flow diagram of 
the systematic literature review
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F I G U R E  2  The period of follow‐up 
in which a significant difference in lung 
cancer mortality (gray and black bars) or 
all‐cause mortality (black bars) can be found 
by number of high‐risk people (men and 
women who smoked at least 30 pack‐years 
and who currently smoke or quit less than 
15 years ago) in each arm
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F I G U R E  3  The period of follow‐up 
in which a significant difference in breast 
cancer mortality (gray and black bars) or 
all‐cause mortality (black bars) can be found 
by number of women in each arm
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lived 41 years longer (on average 15 days per participant, or 
8.2 life‐years saved per colorectal cancer death prevented). 
A significant difference in colorectal cancer mortality could 
be shown after 18 years for a sample size of 8000 people in 
each arm (Figure 4). With larger sample sizes, a significant 
difference could be found after 4 years. To show a signifi-
cant effect in all‐cause mortality, 12 years of follow‐up and 
minimal 600 000 people were needed in each arm.
An example of the confidence intervals of the rate ratios 
of cancer‐specific mortality and all‐cause mortality is pre-
sented in Appendix 3.
4 |  DISCUSSION
The results show that cancer screening trials are potentially 
able to demonstrate a significant reduction in all‐cause mor-
tality due to screening, as long as the sample sizes of the tri-
als are very large. Depending on the type of cancer 40 000 
to 600 000 participants per arm are needed to demonstrate a 
significant reduction. On the other hand, timing is also im-
portant. For the smallest possible sample sizes, a significant 
effect can only be demonstrated between 11 to 20 years of 
follow‐up. Besides differences in natural history of the can-
cers, also differences in screening ages, intervals, and the 
improvement in prognosis due to screening influence the 
required sample size. The model predictions were close to 
the predictions found in the literature review.
The differences in results between the three cancer types 
relate to the natural history of the cancers: the incidence 
level, lead‐time, and survival. A lung cancer screening trial 
that includes high‐risk individuals has the most potential to 
demonstrate a significant effect in all‐cause mortality at rea-
sonable sample sizes. This is because of the high incidence of 
the disease and the low survival rate. In addition, lung cancer 
is generally fast‐growing and has a short lead‐time, therefore 
a significant effect can already be demonstrated after a few 
years. In contrast, colorectal cancer grows slower, the lead‐
time is longer and the survival is higher. Therefore, the sam-
ple size needs to be much larger and the follow‐up longer.
In most cases, the required sample size exceeds the sam-
ple sizes of the trials that have been performed: breast cancer 
screening trials had between 20 000 and 80 000 participants,3 
lung cancer screening trials 2400 and 54 000 participants,13,40 
and colorectal cancer screening trials 30  000 and 180  000 
participants.11 Therefore, it is not surprising that a reduction 
in all‐cause mortality has been found in just one lung can-
cer screening trial so far. It would be unrealistic to require 
that cancer screening trials lead to a reduction in all‐cause 
mortality, given that their primary aim is to evaluate the po-
tential to reduce a cancer‐specific mortality. However, other‐
cause mortality should be carefully monitored in screening 
F I G U R E  4  The period of follow‐up in 
which a significant difference in colorectal 
cancer mortality (gray and black bars) or 
all‐cause mortality (black bars) can be found 
by number of people in each arm using 
flexible sigmoidoscopy once in a lifetime in 
the screened arm
0 5 10 15 20 25 30 35
600 000
500 000
400 000
300 000
200 000
100 000
90 000
80 000
70 000
60 000
50 000
40 000
30 000
20 000
10 000
8000
6000
4000
2000
Year of follow-up
Sa
m
pl
e 
si
ze
 p
er
 a
rm
   | 7HEIJNSDIJK Et al
T
A
B
L
E
 1
 
Th
e r
es
ul
ts 
of
 th
e s
ys
tem
ati
c r
ev
iew
. T
he
 ch
ar
ac
ter
ist
ics
 an
d r
es
ul
ts 
of
 th
e i
nc
lu
de
d p
ap
er
s a
re
 de
sc
rib
ed
 an
d c
om
pa
re
d w
ith
 M
IS
CA
N 
m
od
eli
ng
 es
tim
ate
s
Ar
tic
le 
re
fer
en
ce
Ca
nc
er
 
ty
pe
Na
m
e o
f t
he
 
m
ea
su
re
d 
pa
ra
m
ete
r
Re
su
lts
 of
 th
e m
ea
su
re
d 
pa
ra
m
ete
r
M
od
el 
ty
pe
M
od
ell
ed
 p
op
ul
at
ion
Sc
re
en
 p
ro
gr
am
Ti
m
efr
am
e 
fo
r m
od
el 
pr
ed
ict
ion
s
Co
m
pa
rin
g r
es
ul
ts 
wi
th
 
M
IS
CA
N 
es
tim
at
es
Ca
rre
ra
s, 
20
12
34
Lu
ng
Al
l‐c
au
se
 sm
ok
-
in
g a
ttr
ib
ut
ab
le 
de
ath
s
Re
du
cti
on
 fo
r t
he
 sc
re
en
ed
 
po
pu
lat
io
n a
fte
r 5
, 1
5, 
25
 ye
ar
s:
W
om
en
: 1
.4%
, 1
.5%
, 2
.3%
M
en
: 1
.8%
, 1
.6%
, 1
.9%
M
od
el 
ty
pe
 is
 no
t 
cle
ar
ly
 de
fie
d
M
od
eli
ng
 as
su
m
p-
tio
ns
 w
er
e b
as
ed
 on
 
NL
ST
 tr
ial
Ita
lia
n p
op
ul
ati
on
 be
-
tw
ee
n 1
98
6 a
nd
 20
09
 
(m
od
el 
ad
ju
ste
d 
wi
th
 It
ali
an
 sm
ok
in
g 
ha
bi
ts)
Th
re
e r
ou
nd
s o
f 
an
nu
al 
CT
 sc
re
en
-
in
g f
or
 cu
rre
nt
 
an
d f
or
m
er
 he
av
y 
sm
ok
er
s
Ag
e r
an
ge
: 
55
‐7
4 y
ea
rs
20
15
‐2
02
0
20
15
‐2
03
0
20
15
‐2
04
0 
(5
, 1
5 a
nd
 
25
 ye
ar
s)
No
t c
om
pa
ra
bl
e
M
IS
CA
N 
es
tim
ate
s 
all
‐c
au
se
 de
ath
s a
nd
 no
t 
sm
ok
in
g‐
att
rib
ut
ab
le 
de
ath
.
M
an
se
r, 
20
05
35
Lu
ng
Al
l‐c
au
se
 
m
or
tal
ity
Re
du
cti
on
 in
 al
l‐c
au
se
 m
or
tal
-
ity
 ‐ 
sc
re
en
in
g v
s. 
co
nt
ro
l 
ar
m
: 2
.1%
M
ar
ko
v m
od
el:
 
Us
in
g 1
0 d
iff
er
en
t 
he
alt
h s
tat
es
 w
ith
 
a c
yc
le 
pe
rio
d o
f 
3 m
on
th
s
Tw
o h
yp
ot
he
tic
al 
Au
str
ali
an
 co
ho
rts
: 
Sc
re
en
 an
d c
on
tro
l 
ar
m
 of
 10
 00
0 h
ig
h‐
ris
k m
ale
 sm
ok
er
s
An
nu
al 
CT
 sc
re
en
-
in
g f
or
 hi
gh
‐ri
sk
 
m
ale
 cu
rre
nt
 
sm
ok
er
sa
Ag
e r
an
ge
 
60
‐6
4 y
ea
rs
15
 ye
ar
s a
fte
r 
th
e o
ns
et 
of
 
sc
re
en
in
g
Co
m
pa
ra
bl
e
M
IS
CA
N 
es
tim
ate
s: 
1.9
% 
af
ter
 15
 ye
ar
s
M
cM
ah
on
, 
20
08
36
Lu
ng
Nu
m
be
r o
f a
ll‐
ca
us
e d
ea
th
s
Re
lat
iv
e r
ed
uc
tio
n f
or
 th
e 
co
ho
rt 
‐ s
cr
ee
ni
ng
 vs
. c
on
tro
l 
ar
m
6 y
ea
rs:
 3.
6%
 (1
57
 vs
. 1
62
.8)
10
 ye
ar
s: 
2.9
% 
(2
93
.6 
vs
. 
30
2.3
)
15
 ye
ar
s: 
1.9
% 
(5
01
 vs
. 5
10
.7)
Lu
ng
 C
an
ce
r P
ol
icy
 
M
od
el:
 P
ati
en
t‐l
ev
el 
m
icr
os
im
ul
ati
on
 
m
od
el 
co
ns
id
er
in
g 
in
di
vi
du
al 
he
ter
og
e-
ne
ity
 in
 ri
sk
 fa
cto
rs 
an
d e
ve
nt
 ra
tes
.
M
ay
o C
lin
ic 
he
lic
al 
CT
 sc
re
en
in
g s
tu
dy
: 
15
20
 pa
rti
cip
an
ts,
 
m
ea
n a
ge
: 5
9 y
ea
rs,
 
en
ro
llm
en
t: 
Ja
nu
ar
y 
to
 D
ec
em
be
r 1
99
9
An
nu
al 
he
lic
al 
CT
 
ex
am
in
ati
on
s f
or
 
cu
rre
nt
 an
d f
or
m
er
 
sm
ok
er
s
Ag
e r
an
ge
: 
50
‐8
5 y
ea
rs
6, 
10
 an
d 
15
 ye
ar
s a
fte
r 
th
e s
tu
dy
 
en
ro
llm
en
t
Co
m
pa
ra
bl
e
M
IS
CA
N 
es
tim
ate
s: 
2.3
%,
 2.
4%
 an
d 1
.9%
 
af
ter
 6,
 10
 an
d 1
5 y
ea
rs 
re
sp
ec
tiv
ely
M
ar
sh
all
, 
20
05
37
Br
ea
st
Nu
m
be
r o
f a
ll‐
ca
us
e d
ea
th
s
Re
lat
iv
e r
ed
uc
tio
n f
or
 10
00
 
wo
m
en
 ‐ 
sc
re
en
in
g v
s. 
co
n-
tro
l a
rm
Ag
e 4
0‐
75
:1
.5%
 (2
71
 vs
. 2
75
)
Ag
e 5
0‐
75
:1
.1%
 (2
72
 vs
. 2
75
)
M
ath
em
ati
ca
l m
od
el 
ba
se
d o
n U
S 
m
or
tal
-
ity
 ra
tes
Da
tab
as
e: 
Ce
nt
er
s f
or
 
Di
se
as
e C
on
tro
l a
nd
 
Pr
ev
en
tio
n
US
 w
om
en
Bi
en
ni
al 
m
am
m
og
-
ra
ph
y s
cr
ee
ni
ng
Ag
e r
an
ge
: 4
0‐
75
 
an
d 5
0‐
75
 ye
ar
s
Fr
om
 ag
e 4
0 
un
til
 ag
e 7
5
Co
m
pa
ra
bl
e w
ith
 
lim
ita
tio
n
M
IS
CA
N 
us
es
 di
ffe
re
nt
 
ag
e r
an
ge
: s
cr
ee
ni
ng
 
ag
e 5
0‐
69
M
IS
CA
N 
es
tim
ate
s: 
1.1
% 
af
ter
 10
‐2
0 y
ea
rs
Ph
ar
oa
h, 
20
13
38
Br
ea
st
Nu
m
be
r o
f a
ll 
ca
us
e d
ea
th
s
Re
lat
iv
e r
ed
uc
tio
n f
or
 th
e 
co
ho
rt 
‐ s
cr
ee
ni
ng
 vs
. c
on
tro
l 
ar
m
: 0
.4%
 (2
17
 19
2 v
s. 
21
7 
98
3)
M
ath
em
ati
ca
l m
od
el 
ba
se
d o
n l
ife
 ta
bl
es
 
of
 E
ng
lan
d a
nd
 
W
ale
s u
sin
g d
ata
 
fro
m
 O
ffi
ce
 fo
r 
Na
tio
na
l S
tat
ist
ics
72
9 0
00
 50
‐y
ea
r o
ld
 
wo
m
en
 in
 20
09
 in
 
En
gl
an
d a
nd
 W
ale
s 
36
4 5
00
 fo
r b
ot
h t
he
 
sc
re
en
 an
d c
on
tro
l 
ar
m
s
M
am
m
og
ra
ph
y a
t 
ag
e 5
0 a
nd
 ev
er
y 
th
re
e y
ea
rs 
th
er
e-
af
ter
 un
til
 th
e a
ge
 
of
 70
35
 ye
ar
s o
f 
fo
llo
w‐
up
Co
m
pa
ra
bl
e w
ith
 
lim
ita
tio
n
M
IS
CA
N 
us
es
 bi
en
ni
al 
sc
re
en
in
g i
ns
tea
d o
f 
ev
er
y t
hr
ee
 ye
ar
M
IS
CA
N 
es
tim
ate
s: 
0.3
% 
af
ter
 35
 ye
ar
s
(C
on
tin
ue
s)
8 |   HEIJNSDIJK Et al
Ar
tic
le 
re
fer
en
ce
Ca
nc
er
 
ty
pe
Na
m
e o
f t
he
 
m
ea
su
re
d 
pa
ra
m
ete
r
Re
su
lts
 of
 th
e m
ea
su
re
d 
pa
ra
m
ete
r
M
od
el 
ty
pe
M
od
ell
ed
 p
op
ul
at
ion
Sc
re
en
 p
ro
gr
am
Ti
m
efr
am
e 
fo
r m
od
el 
pr
ed
ict
ion
s
Co
m
pa
rin
g r
es
ul
ts 
wi
th
 
M
IS
CA
N 
es
tim
at
es
Si
gu
rd
ss
on
, 
20
13
39
Co
lo
n
Al
l d
ea
th
s (
als
o 
re
fe
rre
d a
s 
all
 pr
em
atu
re
 
de
ath
s)
Re
du
cti
on
 du
e t
o s
cr
ee
ni
ng
 
pr
og
ra
m
 by
 co
un
try
De
nm
ar
k:
 0.
8%
; F
in
lan
d:
 
0.5
%;
 Ic
ela
nd
: 0
.6%
; 
No
rw
ay
: 0
.9%
; S
we
de
n:
 
0.8
%
M
ath
em
ati
ca
l m
od
el 
ba
se
d o
n C
oc
hr
an
e 
m
eta
‐a
na
ly
sis
, 
na
tio
na
l d
ata
-
ba
nk
s f
ro
m
 N
or
di
c 
co
un
tri
es
 an
d W
HO
 
m
or
tal
ity
 da
tab
as
e
De
nm
ar
k, 
Fi
nl
an
d, 
No
rw
ay
, S
we
de
n 
po
pu
lat
io
n i
n 2
00
9
Ic
ela
nd
 po
pu
lat
io
n f
or
 
th
e p
er
io
d 2
00
5‐
20
09
Bi
an
nu
all
y F
OB
T 
sc
re
en
in
g f
or
 
10
 ye
ar
s
Ag
e r
an
ge
: 
55
‐7
4 y
ea
rs
10
 ye
ar
s f
or
 
th
e a
ge
 gr
ou
p 
55
‐6
5 a
t t
he
 
sta
rt
Co
m
pa
ra
bl
e w
ith
 
lim
ita
tio
n
M
IS
CA
N 
us
es
 F
IT
 
sc
re
en
in
g t
es
t
M
IS
CA
N 
es
tim
ate
s: 
0.6
% 
af
ter
 10
 ye
ar
s
St
an
g, 
20
18
9
Br
ea
st
Ag
e –
sta
nd
ar
d-
ize
d m
or
tal
ity
 
ra
tes
 fo
r a
ll‐
ca
us
e m
or
tal
ity
Ex
pe
cte
d r
ed
uc
tio
n a
ll‐
ca
us
e 
m
or
tal
ity
 ra
te 
wi
th
 sc
re
en
in
g
UK
 (E
ng
lan
d &
 W
ale
s):
 1.
7%
;
Ge
rm
an
y:
 1.
8%
M
ath
em
ati
ca
l m
od
el 
ba
se
d o
n d
ise
as
e‐
sp
ec
ifi
c r
ela
tiv
e r
ate
 
re
du
cti
on
 fr
om
 tr
ial
s 
an
d e
xp
ec
ted
 al
l‐
ca
us
e m
or
tal
ity
 ra
te
UK
 (E
ng
lan
d &
 
W
ale
s) 
an
d G
er
m
an
y
M
am
m
og
ra
ph
y a
ge
 
50
‐6
9 y
ea
rs
No
t r
ep
or
ted
 
(in
 re
fe
re
nc
es
 
11
 ye
ar
s o
f 
fo
llo
w‐
up
)
Co
m
pa
ra
bl
e
M
IS
CA
N 
es
tim
ate
s: 
1.2
% 
af
ter
 11
 ye
ar
s
St
an
g, 
20
18
9
Co
lo
n
Ag
e –
sta
nd
ar
d-
ize
d m
or
tal
ity
 
ra
tes
 fo
r a
ll‐
ca
us
e m
or
tal
ity
Ex
pe
cte
d r
ed
uc
tio
n a
ll‐
ca
us
e 
m
or
tal
ity
 ra
te 
wi
th
 sc
re
en
in
g
UK
 (E
ng
lan
d &
 W
ale
s):
 1.
2%
;
Ge
rm
an
y:
 1.
0%
M
ath
em
ati
ca
l m
od
el 
ba
se
d o
n d
ise
as
e‐
sp
ec
ifi
c r
ela
tiv
e r
ate
 
re
du
cti
on
 fr
om
 tr
ial
s 
an
d e
xp
ec
ted
 al
l‐
ca
us
e m
or
tal
ity
 ra
te
UK
 (E
ng
lan
d &
 
W
ale
s) 
an
d G
er
m
an
y
Fl
ex
ib
le 
sig
m
oi
-
do
sc
op
y a
ge
 
55
‐6
4 y
ea
rs
No
t r
ep
or
ted
 
(in
 re
fe
re
nc
es
 
11
‐1
2 y
ea
rs 
of
 fo
llo
w‐
up
)
Co
m
pa
ra
bl
e
M
IS
CA
N 
es
tim
ate
s: 
0.8
% 
af
ter
 11
 ye
ar
s
Ab
br
ev
iat
io
ns
: C
T,
 co
m
pu
ted
 to
m
og
ra
ph
y;
 U
S,
 U
ni
ted
 S
tat
es
 of
 A
m
er
ica
; W
HO
, W
or
ld
 H
ea
lth
 O
rg
an
iza
tio
n;
 F
OB
T,
 fe
ca
l o
cc
ul
t b
lo
od
 te
st;
 N
LS
T,
 N
ati
on
al 
Lu
ng
 S
cr
ee
ni
ng
 T
ria
l.
a In
 se
ns
iti
vi
ty
 an
aly
se
s a
lso
 fe
m
ale
 cu
rre
nt
 sm
ok
er
s a
nd
 ot
he
r a
ge
 gr
ou
ps
. 
T
A
B
L
E
 1
 
(C
on
tin
ue
d)
   | 9HEIJNSDIJK Et al
trials, to assure that screening does not increase all‐cause 
mortality.6,41 Screening can increase the all‐cause mortality 
when the screen test can lead to complications (e.g., colonos-
copy), the treatment has complications, or when people that 
are screened maintain a unhealthy lifestyle due to a “health 
certificate effect” (e.g., smokers who continue smoking after 
a negative CT‐scan). A meta‐analysis of the breast cancer 
screening trials showed that the all‐cause death rate was not 
significantly reduced by screening and that screening did not 
induce excess mortality.42
In the hypothetical trial a difference in all‐cause mortal-
ity could be found using 600 000 participants in each arm, 
whereas the meta‐analysis of four flexible sigmoidoscopy 
trials of 458  000 participants already found a statistically 
significant effect on all‐cause mortality (RR 0.975; 95%CI: 
0.959‐0.992).20 Maybe this difference in required sample size 
is related to the characteristics of the four trials (e.g., target 
age, life expectancy, cancer incidence, all‐cause mortality 
correction) that were not taken fully into account in our sim-
ulation of an average trial. Another explanation is that the 
meta‐analysis found a significant result even though there 
was not the power to find it. Since a lot of countries imple-
mented FIT screening, we also simulated a colorectal can-
cer screening trial using biennial FIT screening for the ages 
55‐75. The results are very similar to the simulated flexible 
sigmoidoscopy trial (Appendix 2).
T A B L E  2  The cumulative differences (diff) in cancer‐specific deaths, all‐cause deaths, and life‐years per 1000 participants in each arm
Follow‐up year Cumulative lung cancer deaths Cumulative all‐cause deaths Cumulative life‐years
  control screen diff control screen diff control screen diff
Lung cancer screening
5 19 17 −2 123 121 −2 4762 4765 3
10 41 32 −9 300 293 −7 8712 8739 27
15 60 46 −14 494 484 −10 11 730 11 802 72
20 76 58 −18 680 671 −9 13 787 13 907 120
25 87 67 −20 829 822 −7 14 995 15 155 160
30 92 72 −20 928 925 −3 15 583 15 765 182
35 95 75 −20 978 977 −1 15 801 15 993 192
40 96 76 −20 996 996 0 15 856 16 051 195
45 96 76 −20 1000 1000 0 15 863 16 058 195
Breast cancer screening
5 1 1 0 32 32 0 4925 4925 0
10 3 2 −1 82 81 −1 9650 9653 3
15 7 5 −2 159 157 −2 14 062 14 072 10
20 13 9 −4 276 273 −3 17 990 18 014 24
25 18 13 −5 437 433 −4 21 221 21 262 41
30 23 17 −6 618 615 −3 23 581 23 640 59
35 27 20 −7 790 787 −3 25 043 25 117 74
40 29 22 −7 912 911 −1 25 767 25 850 83
45 29 22 −7 977 976 −1 26 024 26 110 86
50 29 22 −7 1000 1000 0 26 070 26 158 88
Colorectal cancer screening
5 3 3 0 71 71 0 4834 4835 1
10 7 6 −1 177 175 −2 9231 9236 5
15 12 9 −3 323 321 −2 12 998 13 012 14
20 16 12 −4 502 500 −2 15 943 15 968 25
25 19 15 −4 683 682 −1 17 972 18 005 33
30 22 17 −5 835 834 −1 19 156 19 194 38
35 23 18 −5 935 935 0 19 711 19 751 40
40 23 18 −5 984 984 0 19 894 19 935 41
45 23 18 −5 1000 1000 0 19 927 19 968 41
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A limitation is that we did not take a healthy screenee 
effect into account, which may lead to a smaller difference in 
all‐cause deaths. Also, the breast and lung cancer model did 
not include death due to cancer treatment. When more can-
cers are detected in the first years of a screening trial, or due 
to overdiagnosis, more deaths due to treatment are expected, 
especially for lung cancer patients who are often suffering 
from co‐morbidities. Other cancers that can be included in 
this analysis are cervical and prostate cancer. The mortality 
of cervical cancer is probably too low in Western European 
countries to demonstrate a significant effect of screening on 
all‐cause mortality. Also, there have been no trials for cer-
vical cancer screening. In prostate cancer, the mean age of 
dying for the disease is high. Therefore, it is not expected 
that an effect in all‐cause mortality can be found after the 
required follow‐up. Another limitation is that we used fixed 
attendance rates. Although we have chosen these attendance 
rates based on existing screening trials or programs, other 
attendance rates are possible and will influence the required 
sample size. All three models used a cure rate, in which the 
time of death of the cancer can not be extended by screening, 
which may lead to an underestimation of the cancer‐specific 
mortality in the last years of follow‐up. For most years of 
follow‐up in the simulated trials the difference in cancer‐
specific deaths between the screen arm and control arm was 
larger than the difference in all‐cause deaths. An explanation 
is that some of the subjects whose cancer death is prevented 
will die within the same 5‐year period from other causes. 
This probability of dying from other causes increases with 
increasing age.
Although there are only small differences the all‐cause 
deaths between the arms in most follow‐up years, there are 
large differences in the life‐years gained. The model simula-
tions showed that, depending on the cancer, 41‐195 life‐years 
per 1000 participants are gained, which is equal to 8‐12 life‐
years gained per cancer death prevented. The natural history 
of the disease is important: the younger the age at diagno-
sis, the more life‐years can be gained. However, life‐years 
gained after life‐time follow‐up have never been measured in 
screening trials and can only be derived by modeling. In our 
systematic review, the majority of modeling papers that did 
not report all‐cause mortality did report estimated life‐years 
gained as a result of screening.
A strong point of this analysis is that the models used to 
evaluate each cancer screening trial are all MISCAN mod-
els, which means the models have comparable structures and 
assumptions, although of course the models are calibrated 
to various data sources and levels of evidence. The required 
sample size is often calculated using existing statistical sam-
ple size formulas.9 However, screening trials are too complex, 
due to lead‐time and overdiagnosis to calculate the reduction 
in cause‐specific mortality for each year of follow‐up without 
complex models.
In conclusion, cancer screening trials are in theory able to 
demonstrate a significant reduction in all‐cause mortality due 
to screening, but would require sample sizes that are larger 
than most trials that have been performed so far. Therefore, 
statements on all‐cause mortality reductions due to screening 
can not be made on present cancer screening trials. In addi-
tion, a reduction in all‐cause mortality can only be demon-
strated between specific years of follow‐up.
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